Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
3 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, CHRONIC LYMPHOCYTIC LEUKEMIA ARISING IN A PATIENT WITH HODGKIN LYMPHOMA TREATED WITH PERIPHERAL BLOOD STEM CELL TRANSPLANTATION - Case report(Macedonian Association of Anatomists, 2022-06); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, PREDICTIVE INSTRUMENT FOR ASYMPTOMATIC EARLY-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS-SINGLE CENTRE EXPERIENCE(Macedonian Association of Anatomists, 2021-12-28); ; ; ; Stojanovska, SimonaEarly-stage patients with Chronic lymphocytic leukemia (CLL) are diagnosed without need for treatment, managed with following. The distinct course of the disease is diverse, and planing treatment is barely projected at diagnosis. The aim of the study was first-time evaluation of international prognostic score to predict time to first treatment (TFT) in patients with early stage CLL (International Prognostic Score for Early-stage CLL IPS-E). Retrospective study of asymptomatic patients with CLL at early stage of disease in a period of time from January 2011 to January 2021. The median follow-up was 60 months (1-120 months). Individual patient data from 120 treatment-naïve CLL patients with Binet A stage were analyzed to composed International Prognostic Score for Early-stage CLL and correlated with Time to treatment failure (TTF). Using IPS-E patients were distributed in three groups: low risk with 7, 5%, intermediate risk with 44 % and high risk patients 49%. Average TFS was 29, 3 months for low risk group, 28, 6 months for intermediate-risk group and 27,1 months for high-risk group. Using prognostic nomogram we calculated 5 years probability of survival for low, intermediate and high risk group: 73%, 72% and 70% respectively with projected median survival of 9, 1 year for low risk group and 9, 0 year, 8, 9 years for intermediate and high risk groups. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Analysis of Prognostic Factors As Predictors of Treatment Free Survival in Patients with Chronic Lymphocytic Leukemia-Single Centre Experience(2021-08); ; ; ; Krstevska-Balkanov, SvetlanaIntroduction: Chronic lymphocytic leukemia (CLL) is a heterogeneous clonal lymphoproliferative disease originating from activated B lymphocytes that have experienced antigen. The clinical course is very heterogeneous. Some patients never look for treatment, as opposed to others who live and die with an aggressive illness. This clinical heterogeneity is likely a reflection of molecular and cellular heterogeneity, on the basis of which patients with CLL can be divided into subgroups with different clinical-biological characteristics. Aim of the study: Evaluation of prognostic factors in terms of treatment free survival, prognosis and adequate therapeutic approach in patients with CLL. Material and methods: The study is set as retrospective, it includes 300 patients with CLL diagnosed and treated at the University Clinic of Hematology in the period of 10 years (January 2009 - January 2019). The study was performed at the University Clinic for Hematology, Medical Faculty, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia. We evaluate several prognostic factors in terms of treatment free survival. All results were processed with the statistical program SPSS18 software program. Results: The multivariate Cox Proportional model of Treatment free survival of CLL patients confirmed ECOG, Rai Stage, and spleen size that influence on treatment free survival.. Concusion: In our study, multivariate analysis of treatment free survival and overall survival showed ECOG performance status 0,1 and 2 as a factor influencing both overall survival and treatment free survival